TrademarkDir
RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS
LIVE

Serial Number

98324339

Owner

Retinalgenix Technologies Inc.

Attorney

Megan E. Spitz

Filing Date

Dec 20, 2023

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS Trademark

Serial Number: 98324339

RETINALGENIX HIGH-RESOLUTION RETINAL IMAGING - HOME & REMOTE MONITORING - DNA/RNA GPS PHARMACOGENETIC MAPPING - DIAGNOSTIC TESTING & THERAPEUTICS TESTING DRUG VALIDATION & THERAPEUTICS is a trademark filed by Retinalgenix Technologies Inc. on December 20, 2023. The trademark is classified under Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Retinalgenix Technologies Inc. (4 trademarks)

1450 N. McDowell Blvd.
Petaluma, CA 94954

Entity Type: 03

Trademark Details

Filing Date

December 20, 2023

Registration Date

Not Registered

Published for Opposition

July 14, 2026

Goods & Services

High-resolution medical retinal imaging services; Remote monitoring of medical data for medical diagnosis and treatment; DNA and RNA genetic pharmacogenetic mapping for medical diagnostic and treatment purposes; Medical testing for diagnostic or treatment purposes

Filing History

NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 8, 2026 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 14, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jul 14, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 8, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 14, 2026 CNSA
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jun 14, 2026 GNEN
EXAMINER'S AMENDMENT ENTERED
Jun 14, 2026 XAEC
EXAMINERS AMENDMENT E-MAILED
Jun 14, 2026 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jun 14, 2026 CNEA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 24, 2026 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 8, 2025 RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Aug 7, 2025 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Feb 6, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Feb 6, 2025 GNSL
SUSPENSION LETTER WRITTEN
Feb 6, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 3, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 2, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 3, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 3, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 31, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 31, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 31, 2024 CNRT
ASSIGNED TO EXAMINER
May 15, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 1, 2024 NWOS
NEW APPLICATION ENTERED
Dec 20, 2023 NWAP

Related Trademarks

More from this Owner

RETINALGENIX DNA/RNA GPS

RETINALGENIX DNA/RNA GPS

RETINALGENIX DNA/RNA GPS

RETINALGENIX DNA/RNA GPS

RETINALGENIX RNA GPS

RETINALGENIX RNA GPS

RETINALGENIX RNA GPS

RETINALGENIX RNA GPS

RETINALGENIX DNA GPS

RETINALGENIX DNA GPS

RETINALGENIX DNA GPS

RETINALGENIX DNA GPS